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INTRODUCTION
Gaseous transmitters are endogenous gases of small molecular
weight that exert important physiological functions. Although
carbon monoxide (CO) is most notably recognized for its toxicity,
in recent years it has been shown to play an important role as an
endogenous modulator of hemodynamic functions. Since the
initial report in 1993 showing that CO serves as a signaling
molecule (Verma et al., 1993), it has been implicated in a wide
range of cellular responses and pathophysiological states that
stretch well beyond the initial expectations. CO shares some of
the physiological properties of nitric oxide (NO), including
regulation of vascular tone in blood vessels and inhibition of
platelet aggregation by elevating intracellular levels of cGMP. In
addition, CO dilates blood vessels by directly activating calcium-
dependent potassium channels (Wang et al., 1997). CO is
generated during the process of heme degradation, which is
catalyzed by heme oxygenase (HO), causing heme to be converted
to CO, biliverdin and free iron (Maines, 1997). Biliverdin reduced
to bilirubin acts as a potent antioxidant that protects cells against
oxidative stress. Two isoforms of HO are expressed in the heart:
HO-1, inducible, and HO-2, constitutive non-inducible (Peterson
et al., 2009). HO participates in the homeostatic control of
cardiovascular functions, including the regulation of blood
pressure and the prevention of cardiac fibrosis (Wang et al., 2010).
Heme has been reported to act as a promoter of low-density
lipoprotein (LDL) oxidation, generating products that are toxic
to endothelial cells, such as iron, thus suggesting a role of heme
as a crucial risk factor in the development of atherogenesis and
myocardial infarction (Grinshtein et al., 2003; Kumar and
Bandyopadhyay, 2005). However, accumulation of hemin, the
oxidized form of heme, in tissues such as the endothelium
triggers heme degradation into bilirubin, iron and CO by inducing
HO-1 expression and activity (Tsiftsoglou et al., 2006). In mice,
cardiac-restricted HO-1 overexpression protects against ischemia
and reperfusion injury, with improved contractile recovery and
reduced infarct size (Yet et al., 2001). In contrast, transgenic mice
that are heterozygous for targeted disruption of the HO-1 gene,
exhibit exaggerated cardiac injury and dysfunction after ischemia/
reperfusion (I/R) (Yoshida et al., 2001). Very recently, increased
serum levels of HO-1 have been shown to be associated with
decreased severity of coronary artery diseases in individuals with
acute myocardial infarction (Novo et al., 2011). Although we and
others have previously demonstrated that myocardial HO-1
induction by acute treatment with the selective HO-1 inducer
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SUMMARY
We and others have previously demonstrated that heme oxygenase 1 (HO-1) induction by acute hemin administration exerts cardioprotective effects.
Here, we developed a rat model of heart failure to investigate whether a long-term induction of HO-1 by chronic hemin administration exerted
protective effects. Sprague Dawley rats that underwent permanent ligation of the left coronary artery were closely monitored for survival rate analysis
and sacrificed on day 28 post-operation. Administration of hemin (4 mg/kg body weight) every other day for 4 weeks induced a massive increase
in HO-1 expression and activity, as shown by the increased levels of the two main metabolic products of heme degradation, bilirubin and carbon
monoxide (CO). These effects were associated with significant improvement in survival and reduced the extension of myocardial damage. The ischemic
hearts of the hemin-treated animals displayed reduced oxidative stress and apoptosis in comparison with the non-treated rats, as shown by the
decreased levels of lipid peroxidation, free-radical-induced DNA damage, caspase-3 activity and Bax expression. Besides, chronic HO-1 activation
suppressed the elevated levels of myeloperoxidase (MPO) activity, interleukin 1β (IL-1β) production and tumor necrosis factor-α (TNFα) production
that were evoked by the ischemic injury, and increased the plasma level of the anti-inflammatory cytokine IL-10. Interestingly, HO-1 inhibitor zinc
protoporphyrin IX (ZnPP-IX; 1 mg/kg) lowered bilirubin and CO concentrations to control values, thus abolishing all the cardioprotective effects of
hemin. In conclusion, the results demonstrate that chronic HO-1 activation by prolonged administration of hemin improves survival and exerts
protective effects in a rat model of myocardial ischemia by exerting a potent antioxidant activity and disrupting multiple levels of the apoptotic
and inflammatory cascade.
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hemin protects against myocardial I/R injury (Masini et al., 2003;
Giannini et al., 2005; Lakkisto et al., 2009; Yeh et al., 2009), the
effects of chronic hemin administration in a model of prolonged
cardiac ischemia have never been tested and it is not clear
whether a long-term induction of HO-1 is beneficial or
detrimental. Accordingly, this study was undertaken to extend
the investigation of the effects of prolonged HO-1 activation 
by hemin in conditions associated with chronic myocardial
ischemia.
RESULTS
Effect of hemin on survival, infarct size and left ventricular
function in rats exposed to myocardial ischemic injury
In total, 50% of rats that underwent regional myocardial ischemia
and were treated with vehicle survived after 28 days. Chronic hemin
administration significantly improved 28-day survival to 91.70%
(Fig. 1A). The survival benefit of hemin was almost completely
abolished in mice that were pretreated with the HO-1 inhibitor
zinc protoporphyrin IX (ZnPP-IX) before hemin administration
(Fig. 1A).
The results of the computer-assisted morphometry on ischemic
hearts stained with nitroblue tetrazolium showed that
administration of hemin every other day for 4 weeks induced a
significant reduction in the extension of myocardial damage in
comparison with that seen the untreated rats (Fig. 1B). As shown
by echocardiography obtained at 4 weeks after left coronary artery
(LCA) ligation (Fig. 1C), the percent of fractional shortening in the
sham group was significantly higher than that in the ischemic group
(60.58±7.21% and 44.17±5.11%, respectively), suggesting substantial
ventricular dysfunction after 4 weeks of ischemia. In contrast, the
cardiac functional recovery was significantly enhanced
(66.04±5.61%) after hemin administration when compared with the
TRANSLATIONAL IMPACT
Clinical issue
Although chronic heart failure is one of the leading causes of hospitalization,
morbidity and mortality worldwide, effective pharmacological interventions
are currently limited. Recent evidence suggests that induction of heme
oxygenase 1 (HO-1), which is involved in the homeostatic control of
cardiovascular function, by acute treatment with the selective HO-1 inducer
hemin protects against myocardial ischemic injury. In line with this, it has been
demonstrated that increased serum levels of HO-1 are associated with
reductions in severity of coronary artery disease in individuals with acute
myocardial infarction. However, the effects of chronic hemin administration
and long-term induction of HO-1 in a model of prolonged cardiac ischemia
have not yet been investigated.
Results
To determine the effects of long-term HO-1 induction, the authors developed
a rat model of permanent ligation of the left coronary artery. This model
demonstrates ventricular dysfunction and the typical features of
cardiomyocyte injury related to severe oxygen starvation and dysfunction:
severe myofibril hypercontraction and mitochondrial swelling. Administration
of hemin (4 mg/kg body weight) every other day for 4 weeks induced a
significant improvement in survival and reduced the extension of myocardial
damage. Furthermore, the ischemic hearts of the hemin-treated animals
displayed reduced local oxidative stress, apoptosis and inflammatory response
compared with non-treated rats. These beneficial effects were associated with
a massive increase in HO-1 expression and activity. The effects were abolished
by pre-treatment with the selective HO-1 inhibitor zinc protoporphyrin IX
(ZnPP-IX; 1 mg/kg), further validating the cardioprotective role of HO-1
activity.
Implications and future directions
This study demonstrates for the first time that selective and prolonged
administration of agents that activate HO-1 could have a protective effect in
conditions associated with chronic myocardial ischemic injury. The beneficial
effects of HO-1 activation were shown to be due to a combination of anti-
apoptotic and anti-inflammatory effects. This finding lends weight to the
concept that increased expression and activity of HO-1 could be a newly
identified defense mechanism against inflammation and oxidative stress
factors that are present in the ischemic heart. Further studies are warranted to
clarify the potential clinical relevance of these promising findings.
Fig. 1. Effects of hemin on survival, myocardial infarct size and cardiac
function after permanent myocardial ischemia. (A)28-day Kaplan-Meier
survival curve of mice subjected to LCA occlusion in the presence or absence
of hemin (4 mg/kg body weight) and the HO-1 inhibitor ZnPP-IX (1 mg/kg
body weight). (B)Effects of the HO-1 inducer hemin and the HO-1 inhibitor
ZnPP-IX on the extension of infarcted LV myocardium with I/R-induced injury,
evaluated on hearts stained with nitro-blue tetrazolium at 4 weeks of LCA
occlusion. (C)Echocardiographic assessment of fractional shortening (FS%) 
4 weeks following myocardial infarction in the presence or absence of hemin
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ischemic group at the same period. Interestingly, the beneficial
effects of hemin were almost abolished in rats that were pre-treated
with the HO-1 inhibitor ZnPP-IX (Fig. 1C).
Hemin reduces the cytological signs of ischemic injury
When compared with the normal left ventricular (LV) morphology
of sham-operated rats (Fig. 2A), the animals undergoing regional
myocardial ischemia showed the typical features of cardiomyocyte
injury related to severe oxygen starvation and dysfunction, namely
severe myofibril hypercontraction and mitochondrial swelling
(Fig.  2B). The LV myocardium from the rats subjected to the
ischemic insult and treated with 4  mg hemin/kg body weight
showed a marked reduction of the ultrastructural signs of injury,
the most prominent changes being moderate myofibril
hypercontraction and cytoplasmic edema (Fig.  2C). By contrast,
rats subjected to myocardial ischemia and treated with 4  mg
hemin/kg body weight together with the HO-1 inhibitor ZnPP-IX
(1 mg/kg body weight) showed marked signs of ischemic injury,
mainly consisting of severe myofibril hypercontraction (Fig. 2D).
Quantification of ultrastructural tissue injury revealed that cell
damage was significantly increased in the ischemic hearts as
compared with the sham-operated ones and that hemin treatment
robustly reduced the noted markers of cell injury. These beneficial
effects were nullified by pre-treatment with the HO-1 inhibitor
ZnPP-IX (Fig. 2, lower panel).
Effects of hemin on the HO pathway
As shown in Fig. 3A and Fig. 3B, the ischemic insult did not affect
either HO-1 or HO-2 protein expression in the rat heart, whereas
hemin evoked a twofold increase in HO-1, but not HO-2, when
administered to rats that underwent chronic ischemia. Hemin
evoked not only HO-1 overexpression but also a massive increase
in HO-1 activity, as shown by the increased blood levels of the two
main metabolic products of heme degradation, bilirubin (85.7±8.3
nmol/mg protein; Fig.  3B) and CO (30.6±4.3 ppm; Fig.  3C),
compared with measurements made in untreated ischemic animals
(37.8±3.5 nmol/mg protein and 8.1±1.7 ppm, respectively). In rats
that were pre-treated with the HO-1 inhibitor ZnPP-IX, the
observed effects of hemin on HO-1 expression and activity were
completely abolished.
Effects of hemin on oxidative stress induced by ischemic injury
Rats that had undergone permanent coronary occlusion exhibited
a massive increase in tissue markers of oxidative stress, such as the
production of thiobarbituric acid-reactive substances (TBARS; an
index of peroxidation of cell membrane lipids) and 8-hydroxy-2-
deoxyguanosine (8-OHdG; a marker of free radical-induced DNA
damage) (Fig. 4A,B, respectively). The robust increase in TBARS
and 8-OHdG levels was blunted by administration of hemin for 4
weeks. The attenuation in oxidative stress levels obtained after
hemin treatment was reversed by administration of the selective
HO-1 inhibitor ZnPP-IX.
Effects of hemin on leukocyte activation
As shown in Fig. 5A, myocardial ischemia caused a robust increase
in myeloperoxidase (MPO) activity, a specific marker of local
neutrophil activity, in comparison with sham-operated rats
(56.18±8.01 mU MPO/tissue g, 16.92±4.11 mU MPO/tissue g,
respectively; P<0.05). Hemin administration almost completely
abolished the ischemia-induced increase in MPO activity, whereas
the HO-1 inhibitor ZnPP-IX abolished the hemin protective effects.
A massive increase in the blood levels of IL-1β and TNFα, typical
inflammatory cytokines released by activated leukocytes, was
Fig. 2. Ultrastructural examination and quantitation of biopsies of LV
tissues. (A-D)Representative electron micrographs of cardiomyocytes from:
sham-operated rats (A), showing normal myofibrils, mitochondria and
organelle complement; rats undergoing LCA occlusion (B), showing severe
myofibril hypercontraction, and mitochondrial swelling (asterisks); rats
subjected to the ischemic insult and treated with 4 mg hemin/kg body weight
(C), showing cytoplasmic edema, moderate myofibril hypercontraction and
nearly normal microvessels; and rats subjected to the ischemic insult and
treated with 4 mg hemin/kg body weight and the HO-1 inhibitor ZnPP-IX
(1 mg/kg body weight) (D), showing severe myofibril hypercontraction. Scale
bar: 1 μm. Lower panel: the quantification of ultrastructural tissue injury
showed the beneficial effect of hemin treatment in reducing the signs of
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already detectable after 1 day of ischemia (190.94±11.05 pg/ml and
34.60±2.65 pg/ml, respectively), as compared with the sham-
operated animals (44.26±9.52 pg/ml and 5.40±2.30 pg/ml,
respectively), and it was still maintained at 28 days post-operation,
although at lower levels (Fig. 5B,C, respectively). Administration
of hemin prevented the rise in IL-1β and TNFα levels at day 1 after
ischemia (99.20±11.80 pg/ml and 16.60±2.50 pg/ml, respectively),
and similar results were obtained 28 days post-operation (Fig. 5B,C).
Hemin administration also evoked a drastic increase in plasmatic
content of IL-10, a well-known anti-inflammatory cytokine
(Fig. 5D), whereas IL-10 levels were not significantly affected by
ischemic injury. When rats were pre-treated with the selective HO-
1 inhibitor ZnPP-IX, the protective actions of hemin on serum
cytokine levels were consistently reduced.
Effects of hemin on apoptosis markers
As shown in Fig. 6A, neither ischemia nor hemin administration
modified the basal expression of Bcl-2 protein, a well-known
suppressor of apoptosis. On the contrary, the levels of the
mitochondrial proapoptotic protein Bax were significantly increased
by the ischemic injury and this effect was abolished by exogenous
hemin administration. Therefore, the Bcl-2:Bax ratio, an index of
apoptosis signaling, was significantly reduced in animals subjected
to myocardial ischemia in comparison with sham-operated rats and
this effect was attenuated by treatment with hemin (Fig. 6B). When
compared with sham-operated animals, there was a significant
increase in caspase-3 activity within the ischemic myocardial tissue,
which was significantly prevented by hemin administration (Fig. 6C).
ZnPP-IX almost completely abolished the anti-apoptotic effects
evoked by hemin administration.
DISCUSSION
This study provides compelling evidence that chronic treatment
with hemin, an HO-1 inducer, protects the rat heart from prolonged
ischemic injury. The 4-week hemin regimen resulted in a significant
reduction in infarct size and improvement in functional recovery,
and these effects were associated with a significant increase in HO-
1 myocardial expression. In contrast, we did not detect any change
in HO-2 expression among different groups of animals and we
demonstrated that the beneficial effects of hemin were abolished
by the selective HO-1 inhibitor ZnPP-IX, thus supporting the
notion that hemin cardioprotection was due to regulation of a
subtype-selective expression of these isozymes. We also
documented that induction of HO-1, following exposure to hemin,
resulted in improved enzymatic activity, as shown by increased
levels of the two main metabolites generated during the process of
heme degradation, bilirubin and CO. We speculate that the release
of heme catabolic products might act as an efferent signal to
promote myocardial protection, as also suggested by a previous
study demonstrating that the simultaneous administration of the
two catabolic products of heme degradation reduces myocardial
injury and improves cardiac function in the rat (Brennan et al.,
2005). In our experimental model, the ability of the selective HO-
1 inhibitor ZnPP-IX to lower bilirubin and CO concentrations to
control values suggests that the increase in heme metabolite levels
mostly depends on varied levels of HO-1 and further confirms the
key role of HO-1 activation in hemin cardioprotection.
Although we and others have previously demonstrated that acute
HO-1 upregulation occurs in response to ischemic injury in several
organs, including the heart (Masini et al., 2003; Giannini et al., 2005;
Lakkisto et al., 2009; Yeh et al., 2009), here we show for the first
time that selective and prolonged pharmacological induction of
HO-1 activity significantly ameliorates post-infarction myocardial
remodeling. Recently, protective effects of chronic hemin
administration have also been recorded in a rat model of hepatic
ischemic injury (Fang et al., 2011). Similarly, chronic HO-1
induction has been reported to modulate renal hemodynamics and
renal excretory function in ischemic kidney diseases (Ferenbach et
al., 2010). In fact, although renal deposit of heme proteins can
induce tubular injury and, thus, contribute to decreased kidney
Fig. 3. Effects of hemin on the HO-CO pathway. HO-1
and HO-2 expression levels (A) and related densitometric
analysis (B), bilirubin production in heart homogenates (C)
and CO blood values (D) were measured subsequent to
sham operation (Sham) or chronic myocardial ischemia
(vehicle). Rats were administered hemin or hemin+ZnPP-IX,
as described in the Materials and Methods. Densitometric
analysis of the related bands is expressed as relative optical
density (OD) of the bands, corrected for the corresponding
β-actin content and normalized using the related sham-
operated band. Data are means ± s.e.m. of three separate
experiments for western blot and five animals per group for
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function, HO-1 has been demonstrated to be rapidly upregulated
in the kidney exposed to heme proteins (Nath and Katusic, 2012).
Such autoregulatory HO-1 induction represents a unique
countervailing response that mitigates the sensitivity to organ
injury. Although the products of HO-1 are capable of activating an
array of downstream cytoprotective responses, the mechanisms
underlying these remain poorly understood and we are still missing
a unified theory to explain the protective effects of hemin. Initially,
the protective role of HO-1 induction against ischemic injury has
been related to the potent antioxidant activity of the products of
the HO system. A large-scale prospective study of British men
revealed that subjects in the midrange of serum bilirubin
concentration had the lowest incidence of ischemic heart disease
relative to those subjects displaying the lowest fifth of serum
bilirubin distribution (Breimer et al., 1994).
High serum bilirubin levels have also been associated with a
decreased risk for the development of coronary artery disease and
atherosclerosis in humans (Mayer, 2000). In keeping with these
previous reports, here we show that hemin administration evokes
bilirubin production and increased CO blood levels with a
successive remarkable decrease in tissue markers of oxidative
stress and free-radical-induced DNA damage. Recent findings have
led to a re-definition of the HO-1 pathway as not only an anti-
oxidative mechanism but also a more complex and better
coordinated cytoprotective system, with effects on several
inflammatory and apoptotic signal transduction pathways
(Abraham and Kappas, 2005). Accordingly, in the present study we
found that hemin-induced improved outcome is accompanied by
reductions in leukocyte activation as well as cardiomyocyte
apoptosis and these beneficial effects are almost completely
reversed by the administration of the selective HO-1 inhibitor
ZnPP-IX, thus further confirming the key role of HO-1 induction
in myocardial protection. Chronic hemin administration almost
suppresses the elevated levels of MPO activity and IL-1β and TNFα
production evoked by the ischemic injury and increases the plasma
level of the anti-inflammatory cytokine IL-10, which suggests a shift
from a balanced cytokine response to an anti-inflammatory state.
The suppression of inflammatory cytokines by hemin can be
explained, at least in part, by hemin-induced CO overproduction,
because CO has been previously proved to exert potent anti-
inflammatory effects at low concentrations. In a murine model, CO
preconditioning had resulted in the reduction of serum TNFα, IL-
1β and IL-6 (Otterbein et al., 2000; Morse et al., 2003). As recently
reported, the main mechanisms whereby CO affects the
inflammatory response evoked by the ischemic injury include the
downregulation of Toll-like receptor trafficking and activation
(Wang et al., 2009), direct activation of the p38 mitogen-activated
protein kinase (Otterbein et al., 2000), and the increased expression
of the 70-kDa heat-shock protein (Kim et al., 2005). In addition,
HO-1 activation has been demonstrated to downregulate the
inflammatory response by blocking the release of NO from
inducible NO synthase (iNOS) and the expression of granulocyte-
macrophage colony-stimulating factor (Zuckerbraun et al., 2005).
Thus, it is possible that production of CO, as a result of increased
expression and activity of HO-1, could be a newly identified
defense mechanism against inflammation and other related stress
factors present in the ischemic heart.
Complementary to the attenuation in the inflammatory response,
hemin further reduces myocardial apoptosis. Apoptosis with an
increase in the activation of caspase-3 has been reported in
cardiomyocytes of patients undergoing transplantation (Narula et
al., 1999). Cardiac-specific overexpression of the anti-apoptotic
regulator Bcl-2 substantially reduces infarct size, cardiac myocyte
apoptosis and cardiac dysfunction following myocardial infarction
(Chen et al., 2001). Similarly, mice lacking the multidomain pro-
apoptotic Bax demonstrate reductions in myocardial infarct size
and dysfunction. The cellular stoichiometry of Bcl-2 family
members compared with their pro-apoptotic homolog, Bax, clearly
defines the vulnerability of the cell to most death stimuli. In our
study, hemin administration reduced the increase in pro-apoptotic
Bax levels induced by the ischemic insult and thereby reversed the
Bcl-2:Bax ratio. Besides, hemin administration prevented caspase-
3 activation, thus providing a further crucial lead in defining hemin
anti-apoptotic properties. Our findings are in keeping with the
study of Tang and colleagues showing that a plasmid-mediated HO-
1 gene-transfer strategy can provide cardiac-specific protection
from ischemic injury by reducing apoptotic pathways (Tang et al.,
2004). A crucial role in mediating hemin anti-apoptotic effects
seems to be exerted by CO, whose anti-apoptotic potential was first
demonstrated in different cell cultures, including mouse fibroblasts
(Petrache et al., 2000) and endothelial cells (Brouard et al., 2000).
The anti-apoptotic effect of CO involved activation of the p38
MAPK isoform, and inhibition of Fas and/or FasL expression and
other apoptosis-related factors, including caspase-3, Bax proteins
Fig. 4. Effects of hemin on lipid peroxidation and free-radical-induced
DNA damage in LV tissue. TBARS production (A) and 8-OHdG levels (B) were
measured subsequent to sham operation (Sham) or myocardial ischemia in
the absence (vehicle) or presence of hemin (4 mg/kg body weight) or hemin
(4 mg/kg body weight) + ZnPP-IX (1 mg/kg body weight). Data are means ±
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and mitochondrial cytochrome c release (Zhang et al., 2003). An
in vitro study has recently demonstrated that preconditioning of
Kit-positive human cardiac stem cells (hCSCs) with an HO-1
inducer promotes cellular resistance to oxidative stress and
apoptosis through activation of the MAPK signaling pathway and
release of various cytokines (Cai et al., 2012).
In conclusion, our results show for the first time that, when
administered every other day for 4 weeks, hemin induces a
significant reduction in myocardial infarct size in the rat. The
beneficial effect of chronic hemin administration is associated with
the prolonged activation of the HO-1 pathway, which leads to
inhibition of the excessive inflammatory response as well as local
apoptotic activation. This modulation by hemin of both
inflammatory and apoptotic events well exemplifies accumulating
evidence emphasizing the complexity of the molecular and cellular
regulation of the pathophysiology of myocardial ischemia and, most
notably, suggests that the administration of agents that activate HO-
1 might be of benefit in conditions associated with ischemic injury.
However, further studies are warranted to clarify the potential
clinical relevance of our findings.
MATERIALS AND METHODS
Animals
A total of 60 male albino rats, Sprague Dawley strain, weighing
250-300 g (Morini, Reggio Emilia, Italy) were quarantined for 7 days
with laboratory chow (Rodentia, Bergamo, Italy) and water ad
libitum. The experimental protocol was designed in compliance
with the EC Directive 86/609/EEC for animal experiments of the
European Parliament and was approved by the Animal Care
Committee of the University of Florence (Italy).
Surgical procedure and treatments
The rats were anesthetized with intramuscular (i.m.) injection of
a mixture of droperidol (5  mg/kg body weight) and fentanyl
(0.20 mg/kg body weight), supplemented as needed, and monitored
for body temperature, respiration pattern, loss of righting reflex,
unresponsiveness and corneal reflexes. A cannula was inserted into
the trachea and the animals were ventilated with air using a Palmer
pump (Ugo Basile, Comerio, Italy). Subcutaneous peripheral limb
electrodes were inserted and an electrocardiogram (ECG) was
continuously recorded for the entire duration of the experiment.
All rats underwent thoracotomy at the fifth left intercostal space,
the pericardium was opened and a loose 00 braided silk suture was
placed around the left anterior descending coronary artery. The
chest was then closed with a silk suture to minimize heart
displacement. Rats were allowed to equilibrate for 20 minutes to
enable ECG values to stabilize. Permanent ligation of the LCA was
induced by tightening the threads of the coronary suture. Animals
were awakened with an intravenous injection of naloxone
(0.4 mg/kg) and kept for at least 3 hours in a 37°C incubator to
ensure that postoperative recovery was satisfactory. Tail vein blood
was collected at 24 hours after reperfusion for cytokine analysis
and plasma was stored at −80°C until time of assay, after
centrifugation for 10 minutes at 8200 g. Animals were randomly
allocated into five different groups (n=12 per group): the sham
group (rats undergoing the same surgical procedures as above but
without the tightening of the coronary sutures); sham hemin
group; vehicle ischemic group; ischemic hemin group; and ischemic
hemin+ZnPP-IX group. The vehicle ischemic group was injected
with normal saline intraperitoneally every other day for 4 weeks.
Hemin (4 mg/kg body weight) was administered by intraperitoneal
(i.p.) injection every other day for 4 weeks, starting the same day
as LCA occlusion. The hemin+ZnPP-IX group of rats was pre-
treated with ZnPP-IX (1 mg/kg body weight i.p.) 12 hours before
hemin administration. The doses of hemin and the potent HO-1
inhibitor ZnPP-IX (Ki=3 nM) were chosen based on those
previously shown to protect from ischemic injury in the rat (Masini
et al., 2003; Giannini et al., 2005). Animals were monitored for 28
Fig. 5. Effects of hemin on leukocyte activation induced
by regional chronic ischemia. (A)MPO activity was
measured in myocardial homogenates of sham-operated
rats (sham) and rats that underwent 4 weeks ischemia
(vehicle) in the presence or absence of hemin (4 mg/kg
body weight) or hemin (4 mg/kg body weight) + ZnPP-IX
(1 mg/kg body weight). IL-1β (B), TNFα (C) and IL-10 (D)
levels were measured in the blood of rats exposed to 4
weeks of ischemic injury. Hemin (4 mg/kg body weight) or
hemin (4 mg/kg body weight) + ZnPP-IX (1 mg/kg body
weight) were administered by intraperitoneal injection
every other day for 4 week, starting the same day as LCA
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days for all-cause mortality and a Kaplan-Meier 10-day survival
curve was generated.
Echocardiographic assessment of LV function
Transthoracic echocardiography using a 12-MHz linear array
transducer was performed 1 week before LCA ischemia to avoid
any anesthetic effects using a high-resolution ultrasound system.
At 4 weeks following the myocardial infarction (post myocardial
infarction), echocardiography images were obtained and analyzed
once again. The rats (n=5 in each group) were anesthetized by 3%
isoflurane; loss of righting reflex, unresponsiveness and corneal
reflexes were used to check for successful anesthesia. Rats were
placed in a supine position and their chests were shaved. LV internal
chamber dimension in end-diastole (LVDd) and in end-systole
(LVDs) were measured in each heart. LV fractional shortening (FS%)
was calculated as (LVDd−LVDs)/LVDd×100%.
Analysis of CO blood levels
Double samples of arterial blood were collected in gas-tight tubes
and kept at 4°C until CO analysis, which was performed using an
ultra-trace level gas detection system (RGA3 Reduction Gas
Analyzer, SAES Getters, Milan, Italy), as described elsewhere
(Tarquini et al., 2009).
Determination of infarct size
At 4 weeks after LCA occlusion, the rats were anesthetized with
3% isoflurane, and 2 ml Evans Blue (Sigma Co, St Louis, MO) were
retrogradely injected with a thin catheter inserted into the carotid
artery to delineate the in vivo area at risk (AAR) (Masini et al., 2002).
To distinguish between viable ischemic and infarcted tissue, the p-
nitro blue tetrazolium (NBT) dye exclusion method was used. The
animals were killed by cervical dislocation. Upon removal, the
hearts were attached to a Langendorff apparatus through a cannula
introduced into the aorta and perfused with 10  ml of 1% NBT
dissolved in a modified Tyrode solution, at a constant pressure of
40 cm of water at 37°C for 20 minutes. The hearts were detached
from the cannula, weighed, fixed in buffered 4% formaldehyde for
12 hours, and the ventricles sectioned in 1-mm transverse slices
from the apex to the ligature. In each slice, the bound areas of the
unstained area on the upside surface were traced onto a
superimposed acetate sheet and the encircled area was measured
by computer-assisted morphometry. The LV area, AAR, the area
of infarction of each slide and the total volume of the damaged
myocardium were then determined as previously described (Masini
et al., 2002). All measurements and calculations were performed
by two individuals (A.P. and R.M.), who were blinded to treatment
status.
Ultrastructural examination
Electron microscopic examination was carried out on ultrathin
sections of heart tissue fragments stained with uranyl acetate and
alkaline bismuth subnitrate, and examined under a JEM 1010
electron microscope (Jeol, Tokyo, Japan) at 80 Kv. In each fragment,
two series of six to eight ultrathin sections cut at two different levels
(each series put on an electron microscopy grid) were examined
and photographed. Myocyte injury was quantitated from electron
micrographs (final magnifications ranging from 3000× to 20,000×)
using a previously described method (Bani et al., 1998). The
criteria used are reported in Table 1. Each animal was assigned a
score for myocyte injury and the average values (mean ± s.e.m.) of
each group were then calculated.
Determination of HO activity
Cardiac samples were homogenized and incubated for 30 minutes
at 37°C with 50  μl of rat liver biliverdin reductase to convert
biliverdin to bilirubin (Llesuy and Tomaro, 1994). The level of
bilirubin was measured spectrophotometrically using a Sigma
diagnostic procedure (Sigma, St Louis, MO) as previously reported
(Ndisang et al., 2001).
Fig. 6. Effects of hemin on markers of apoptosis in the hearts of rats that
underwent myocardial ischemia. (A,B)Representative western blot and
corresponding densitometric analysis of the bands showing expression of Bcl-
2 and Bax measured in the hearts of rats at 4 weeks after LCA occlusion in the
presence or absence of hemin (4 mg/kg body weight) or hemin (4 mg/kg body
weight) + ZnPP-IX (1 mg/kg body weight). Each immunoblot is from a single
experiment and is representative of three separate experiments. (C)Caspase-3
activity was revealed by a fluorimetric assay in the hearts of sham-operated
rats (sham) and rats that underwent 4 weeks of ischemia in the presence or
absence of hemin (4 mg/kg body weight) or hemin (4 mg/kg body weight) +
ZnPP-IX (1 mg/kg body weight). Data are means ± s.e.m. of four animals/group
for caspase-3 activity and three separate experiments for western blot
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Evaluation of MPO activity
MPO activity, which can be used as a marker for neutrophil
accumulation in tissues, was determined as previously described
(Bani et al., 1998).
Determination of TBARS
TBARS are end products of cell membrane lipid peroxidation used
as a reliable marker of myocardial cell damage. TBARS were
determined by measurement of the chromogen obtained from the
reaction of MDA with 2-thiobarbituric acid according to Aruoma
et al. (Aruoma et al., 1989).
Determination of 8-OHdG
DNA isolation from cardiac tissue homogenates was performed
according to Masini et al. (Masini et al., 2005). Samples of DNA
extract were used for 8-OHdG determination using a Bioxytech
enzyme immunoassay kit (Oxis, Portland, OR), following the
instructions provided by the manufacturer. The values are expressed
as ng of 8-OHdG per μg proteins.
Measurement of caspase-3 activity
The enzymatic activity of caspase-3 was determined using the Ac-
Asp-Glu-Val-Asp-AMC (Ac-DEVD-AMC; Bachem) fluorescent
substrate (Stennicke and Salvesen, 1997). Substrate cleavage was
monitored fluorimetrically (Spectrofluo JY3 D, Jobin Yvon, Paris,
France) at 380-nm excitation and 460-nm emission wavelengths.
Data are expressed as arbitrary units/mg proteins. One unit of
enzyme activity is defined as the amount of enzyme required to
liberate 40 μmol of Ac-DEVD-AMC over 60 minutes at 37°C.
Determination of TNFα, IL-1β and IL-10 production
Cytokines were measured using commercial enzyme-linked
immunosorbent assay (ELISA) kits (Cayman Chemical, Ann Arbor,
MI), following the protocol provided by the manufacturer, and
results are expressed as pg/ml.
Western blot analysis
Western blots were carried out as previously described (Collino et
al., 2008). Proteins were separated by 10% sodium dodecyl sulphate
(SDS)-PAGE and transferred to polyvinyldenedifluoride
membranes. The membranes were then incubated with primary
and then secondary antibodies and developed using the ECL
detection system. The immunoreactive bands were visualized by
autoradiography and the density of the bands was evaluated
densitometrically using Gel Pro®Analyser 4.5, 2000 software (Media
Cybernetics, Silver Spring, MD).
Statistical analysis
The reported data are expressed as mean ± s.e.m. Statistical
analysis was performed by either one-way analysis of variance
(ANOVA) test followed by Student-Newman-Keuls multiple
comparison test or by Student’s t-test for unpaired values.
Calculations were carried out using a GraphPad Prism 2.0 statistical
program (GraphPad Software, San Diego, CA). P<0.05 was
considered significant.
Materials
Unless stated otherwise, all compounds were purchased from the
Sigma-Aldrich Company Ltd (St Louis, MO). Antibodies against
HO-1, HO-2, Bcl-2 and Bax were from Santa Cruz Biotechnology
(Santa Cruz, CA). Luminol ECL detection reagents were from
Amersham (Buckinghamshire, UK).
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